From: Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting
Ages (years)
N
%
Under 5
11
9%
5-13
18
14.6%
14-25
39
31.7%
26-35
21
17%
36-45
46-55
15
12.2%
Over 55
5
4%
Not specified
3
2.4%
Total
123
100%